Source Post

A Pharma Stock to Consider Buying Before April?

Playing FTSEMar 1, 2026

The creator highlights Axsome Therapeutics as a compelling buy ahead of a major FDA catalyst in April, citing strong revenue growth and a clear path to profitability.

Linked Mentions

Tickers discussed in this post

PFENeutralLow ConvictionResearch Only

Pfizer is mentioned as a hypothetical acquirer for biotech firms, with no specific recommendation on its own shares.

AXSMBullishHigh ConvictionSignal-backedPrimary

Axsome Therapeutics is a buy due to its narrowing losses, high gross margins, and a major upcoming FDA decision for Alzheimer's agitation.

Linked Signals

Tracked calls opened from this post

AXSM
buy opened Mar 1, 2026
+35.55%